Other

University of Cincinnati

Sucampo Ag

John Cuppoletti

Ryuji Ueno

Nick H Langdon

A method for determining the amount of pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample.

Methods for ionophorically screening pore forming bacterial protein toxins and receptors

A method for determining the amount of live pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample. A kit for determining the amount of live pore forming bacterial toxin protein present in the sample is also provided.

Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin Fisopropyl ester.

Method for treating macular degeneration

One embodiment of the present invention is directed to methods for ionophorically screening pore forming bacterial protein toxins and receptors for insect toxicity. The method includes: a) forming a membrane comprising a lipid and an insect receptor, b) contacting the membrane with the pore forming bacterial protein toxin and an ion solution, and c) measuring ion flow through the membrane. Also provided are a method and kit for determining the amount of live pore forming bacterial toxin protein in a sample.

One embodiment of the present invention is directed to methods for ionophorically screening pore forming bacterial protein toxins and receptors. The method includes: a) forming a membrane comprising a lipid and a receptor, b) contacting the membrane with the pore forming bacterial protein toxin and an ion solution, and c) measuring ion flow through the membrane.

Functional biological synthetic composite (BSC) membranes comprising phospholipids, biological membrane proteins and porous supports or membranes are provided. Lipid bilayers are formed on porous polycarbonate (PC), polyethylene terephthalate (PETE) and poly (I-lactic acid) (PLLA) membranes and in laser-drilled pores in a multi-well plastic plate as measured by increased resistance or decreased currents. BSC's comprising functional reconstituted Kv1.5 K channel and/or H/K ATPase transport proteins are also provided c inhibitor), methods of manufacture, and high throughput screening assays employing the inventive membranes are also provided.

Selectively permeable membranes on porous substrates

A selectively permeable film supported membrane comprises a selectively permeable film comprising at least one ionomer; a bilayer formed on the film; and at least one transport substance incorporated into the bilayer. Methods for forming a selectively permeable film supported membrane comprise the steps of forming a bilayer on a selectively permeable film comprising at least one ionomer and incorporating at least one transport substance into the bilayer. Fuel cells, toxins detectors and protective devices comprise a selectively permeable film supported membrane.

Selectively permeable film supported membrane

Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.

Chloride channel opener

Methods for studying ion channels comprise incorporating an ion channel onto the surface of a solid-supported membrane; applying a potential to the solid-supported membrane; and measuring an electrical signal of the ion channel. Methods for identifying or screening compounds that bind to ion channels employ an ion channel incorporated onto a solid-supported membrane.

Methods for studying ion channels incorporated onto a solid-supported membrane

This invention provides a method for increasing the permeability of epithelial cells to a chloride ion in a subject comprising administering a permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The invention also relates to a method of treating cystic fibrosis comprising administering an epithelial cell chloride permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The benzimidazole compound having chloride channel activation activity for use in this invention includes a 2-[(pyridyl)-methylsulfinyl or -methylthio]benzimidazole derivatives and salts thereof, for instance. Specifically, these include the compounds omeprazole, lansoprazole, thimoprazole and pantoprazole. When appropriately applied, these compounds can correct detective chloride transport, increasing the salt and water flux in diseased tissues to levels closer to those of normal tissues thus reducing life-threatening complications.

Activation of chloride channels for correction of defective chloride

This invention relates generally to medical treatment methods. Specifically, the invention relates to methodology for the correction of defective chloride transport by activation of chloride channels of the lung and other epithelia using genetic or chemical modification. These methods relate to the treatment of epithelia with compounds which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These methods also relate to the treatment of epithelia with gene therapy to introduce chloride channels genes with site mutations which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These treatments will reduce life-threatening complications frequently found in diseases such as cystic fibrosis. These methods of activation of chloride channels also comprise treatment of chloride channels with amidation reactions.

Chemical modification of chloride channels as a treatment for cystic

A coverslip holder assembly for a front face fluorimetry flow cell has a holder body and a hingedly attached clamp for releasably maintaining a coverslip adjacent the front face of the holder body and flow cell. The assembly is preferably a unitary arrangement wherein the clamp is hingedly mounted adjacent the bottom end of the front face of the holder body, and has a convenient snap lock release mechanism at its top end to selectively lock the coverslip in flush arrangement with the front face. The holder assembly can provide a biased snug fit with a variety of cuvettes or similar sample vessels, and enables the use of highly colored or fluorescent compounds for perfusion in front face fluorimetry operations.

Growing community of inventors

Cincinnati, OH, United States of America

John Cuppoletti